Published in Gastroenterology on May 01, 1991
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Extraintestinal manifestations of inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2008) 1.64
Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut (1992) 1.60
Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut (1992) 1.60
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut (1993) 1.39
Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34
Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci (1999) 1.34
Churg-Strauss syndrome. Thorax (2000) 1.27
Immunoregulation in the gut: success and failures in human disease. Gut (2002) 1.25
Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol (2003) 1.21
Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol (1992) 1.21
Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis. J Clin Pathol (1994) 1.17
Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol (2005) 1.16
pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol (1998) 1.13
Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol (1994) 1.12
Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis (1993) 1.11
Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut (1992) 0.99
Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol (1998) 0.97
The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg (1992) 0.96
The clinical relevance of ANCA in vasculitis. Clin Exp Immunol (1993) 0.95
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis (2004) 0.94
Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens. Inflamm Bowel Dis (2011) 0.92
Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol (2001) 0.91
Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol (1999) 0.90
PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One (2014) 0.88
Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol (1995) 0.88
Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis. Dig Dis Sci (1999) 0.87
Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies. ISRN Nephrol (2013) 0.87
Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med (2010) 0.85
IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. Clin Exp Immunol (2003) 0.85
Antimyeloperoxidase antibodies in individuals with occupational exposure to silica. Ann Rheum Dis (1996) 0.84
Low Serum Alpha-Antitrypsin Associated with Anti-PR-3 ANCA in Autistic Children with GI Disease. Genomics Insights (2009) 0.82
Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases. World J Gastroenterol (2013) 0.82
Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Gut (1996) 0.82
Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol (2008) 0.81
Sclerosing cholangitis and biliary tract calculi--primary or secondary? Gut (1992) 0.81
Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. Gut (1997) 0.81
Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood? Gut (1993) 0.79
Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. Gut (1993) 0.79
A novel specificity of anticytoplasmic autoantibodies directed against eosinophil peroxidase. Clin Exp Immunol (1993) 0.79
Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance. Clin Exp Immunol (2007) 0.76
Tissue distribution of autoantigen specific for primary sclerosing cholangitis. J Clin Pathol (1993) 0.75
IFNG rs1861494 polymorphism is associated with IBD disease severity and functional changes in both IFNG methylation and protein secretion. Inflamm Bowel Dis (2014) 0.75
Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therap Adv Gastroenterol (2016) 0.75
Antineutrophil cytoplasmic antibody and the gastroenterologist. J R Soc Med (1992) 0.75
An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci (1997) 0.75
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Biliary tract cancers. N Engl J Med (1999) 6.36
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut (2010) 3.67
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology (1980) 3.57
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med (1996) 3.56
Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet (1994) 3.22
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology (1996) 3.08
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol (1997) 3.05
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol (1990) 2.98
Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med (2000) 2.93
Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology (1991) 2.93
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology (1998) 2.75
In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr (2001) 2.73
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut (2008) 2.69
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res (2000) 2.38
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut (2003) 2.37
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol (2001) 2.36
Current concepts. Primary sclerosing cholangitis. N Engl J Med (1984) 2.35
Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut (1993) 2.35
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol (1997) 2.28
Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl (2000) 2.27
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol (2000) 2.25
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry (2012) 2.16
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 2.16
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek (1999) 2.14
Insulin-dependent diabetes mellitus and coeliac disease. Lancet (1997) 2.14
Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology (2000) 2.10
Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology (1993) 2.10
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology (1994) 2.10
Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis (1995) 2.07
Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther (2014) 2.06
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med (1991) 2.03
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol (2000) 2.03
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. Chest (1990) 1.99
Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther (2001) 1.97
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc (1989) 1.93
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology (1989) 1.89
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest (1987) 1.88
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant (2008) 1.86
Quantification of the placebo response in ulcerative colitis. Gastroenterology (1997) 1.86
Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol (1985) 1.85
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology (1998) 1.84
Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. Gastroenterology (1980) 1.84
Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med P R (1990) 1.79
The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol (1998) 1.78
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1997) 1.77
Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol (2000) 1.77
Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. Proc Natl Acad Sci U S A (1989) 1.77
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis (2001) 1.77
Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology (1996) 1.76
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology (1990) 1.76
Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut (1999) 1.75
A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis (1999) 1.74
Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. Clin Exp Allergy (2010) 1.73
A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis (1995) 1.71
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc (1988) 1.71
Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol (1995) 1.70
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol (2000) 1.70
Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol (1994) 1.69
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology (1990) 1.69
Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol (1998) 1.68
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology (1992) 1.67
The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival. Am J Gastroenterol (2000) 1.65